While Canada is not the largest supplier of U.S. pharmaceuticals, proposed tariffs could significantly increase costs and disrupt supply chains, according to a new analysis.
Customers using Cellares’ automated cell therapy manufacturing services will receive priority review from the agency, leading to accelerated regulatory filings.
